A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
May 11th, 2022
The present protocol describes a two-point injection of lysophosphatidylcholine via a stereotaxic frame to generate a stable and reproducible demyelination model in mice.
Our model is highly relevant to demyelination diseases, especially multiple sclerosis. And it can contribute to the related advancing clinically relevant research. It's a detailed protocol that could directly cause severe demyelination quickly and stably in mice by surgical procedure.
While trying this technique for the first time, be patient, and ensure that coordinates are accurate. Begin by connecting a 32 gauge needle to a 5 microliter syringe. Withdraw 5 microliters of LPC solution for the preparation of the injection.
Next, confirm the depth of anesthesia of the mouse by the lack of toe pinch reflex while the breathing is smooth. Position the mouse in the stereotaxic frame with the dorsal side up, and secure the head with a nose cone and tooth clamp. Fix the mouse to the stereotaxic apparatus with bilateral ear bars.
Ensure that the ear bars are level and the head is horizontal and stable. Disinfect the head skin by wiping with iodophor. Then use scalpel to cut a small incision to about 1.5 centimeters along the midline of the scalp to expose the skull.
Wipe the skill with a cotton swab dipped in 1%hydrogen peroxide until the bregma, lambda, and posterior fontanelle are exposed. Place the syringe on the stereotaxic apparatus. Ensure the horizontal positioning of the animal's head, and locate the corpus callosum.
Once the injection site is determined, record the coordinates, and make a mark with a marker on the skull. Gently drill the marked site with a skull drill. Take care to avoid any bleeding.
Slowly move the needle to the given coordinates. To induce corpus callosum demyelination, inject 2 microliters of LPC solution at each injection site at a rate of 0.4 microliters per minute. After injection, keep the needle in each site for an additional 10 minutes.
Finally, suture the skin with a 4-0 suture, and wait for the animal to wake up within 10 minutes. The representative image shows the detection of the white matter legions via Luxol fast blue staining. From the results, stable demyelination of the corpus callosum can be seen at 10 and 28 days post injection.
The quantification of the demyelination area at different time points is shown here. Through immunofluorescence staining degraded myelin basic protein, a remarkable increase of dMBP was observed in the LPC-injected group at 10 days post injection, which represents myelin loss in the corpus callosum. Western blot analysis of the myelin basic protein, or MBP, expression showed a significant loss of MBP after injection of LPC.
Beta-actin was used as the loading control to measure the baseline expression. Electron microscopy images confirm the myelinated ultrastructure in the corpus callosum of sham group and LPC-injected group. GST-pi is the marker of oligodendrocyte precursor cell, or OPC, differentiation maturation.
After 10 days of LPC injection, the GST-pi decreased compared with the sham group. At the same time, the proliferation ability of oligodendrocytes can be reflected by the ratio of oligodendrocytes proliferate and the total oligodendrocyte lineage cells. The higher ratio represents more proliferation of oligodendrocytes after 10 days post injection.
The representative images show the mice's swimming path in each group, in the platform's presence and after removing the platform. The results suggest that the spatial memory of demyelinated mice is significantly impaired in the two-point LPC injection model. While attempting this procedure, make sure that the injection rate is accurate, and keep the needle in each site for an additional 10 minutes.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol details a two-point injection of lysophosphatidylcholine (LPC) using a stereotaxic frame to create a stable demyelination model in mice. It provides a method relevant for studying demyelination diseases, particularly multiple sclerosis, enabling research into the mechanisms and implications of demyelination.
Key Study Components
Area of Science
- Neuroscience
- Demyelination research
- Mouse models of disease
Background
- Understanding demyelination is crucial for developing treatments for diseases like multiple sclerosis.
- The outlined procedure is intended to induce rapid and reproducible demyelination in laboratory settings.
- Accurate surgical technique is important for the procedure's success.
- Histological analyses such as Luxol fast blue staining are used to evaluate the model.
Purpose of Study
- To establish a reliable model for studying the mechanisms of demyelination.
- To facilitate research into potential therapeutic interventions for demyelination-related conditions.
- To provide detailed surgical protocols that yield quantifiable results.
Methods Used
- The model involves a stereotaxic surgical approach for LPC injections.
- Mice are injected with LPC solution at precise anatomical locations, specifically targeting the corpus callosum.
- Each injection involves 2 microliters of LPC administered at a controlled rate.
- Post-operative assessments at 10 and 28 days provide key outcome measurements.
- Histological techniques such as immunofluorescence and Western blotting are employed to analyze myelin loss.
Main Results
- Stable demyelination in the corpus callosum was achieved, observable through histological staining at multiple time points.
- An increase in markers indicative of myelin loss was confirmed through various analyses.
- Behavioral assessments indicated significant impairments in spatial memory following demyelination.
- Results suggest alterations in oligodendrocyte proliferation and differentiation in response to LPC treatment.
Conclusions
- This study successfully establishes a model for exploring the dynamics of demyelination and potential therapeutic strategies.
- The findings provide insights into neuronal mechanisms underlying demyelination and the role of oligodendrocytes.
- This model may advance understanding of multiple sclerosis and similar conditions.
Frequently Asked Questions
Executive Industry Relevance
The stably established two-point LPC injection model enables rapid and reproducible induction of focal demyelination in mice, directly supporting discovery-stage research in demyelinating diseases such as multiple sclerosis. This model provides a robust platform for mechanistic de-risking, target validation, and quantitative assessment of myelin loss and repair. Its reproducibility and quantitative outputs position it as a critical tool for preclinical evaluation and portfolio triage in neuroinflammatory disease pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of demyelination mechanisms and pathway involvement in disease-relevant systems.
- Supports functional target validation by quantifying myelin loss and oligodendrocyte responses.
- Facilitates predictive confidence in therapeutic hypothesis testing for neuroinflammatory conditions.
Screening & Assay Development
- Provides a validated in vivo system for downstream compound screening targeting remyelination or neuroprotection.
- Delivers standardized, reproducible demyelination suitable for quantitative histological and behavioral assays.
- Enables reliable evaluation of candidate interventions with measurable endpoints.
Translational & Preclinical Research
- Aligns with disease-relevant pathology observed in multiple sclerosis, supporting translational biomarker development.
- Ensures continuity from mechanistic discovery through preclinical validation of therapeutic strategies.
- Reduces biological risk by modeling acute demyelination and functional impairment in vivo.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies with translational research in demyelinating diseases.
- Discovery Biology: Supports hypothesis testing and pathway clarification through quantifiable demyelination and oligodendrocyte analysis.
- Screening: Provides assay-ready, reproducible outputs for compound evaluation and dose-response studies.
- Analytics: Enables quantitative measurement of myelin loss, protein expression, and behavioral deficits for comparative analysis.
- Translational Research: Models disease-relevant endpoints for biomarker alignment and preclinical validation.
- Enterprise Reuse: Offers a standardized, reusable in vivo platform for multiple neuroinflammatory research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in demyelination research.
- Operational Value: Delivers standardized, reproducible, and scalable in vivo modeling for cross-program use.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust preclinical data.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of neuroinflammatory disease assets.
Implementation Considerations
- Requires expertise in stereotaxic surgery and precise anatomical targeting in mice.
- Demands access to histological, immunofluorescence, and behavioral analysis infrastructure.
- Necessitates cross-team standardization of injection coordinates and rate for reproducibility.
- Adaptation to other CNS regions or disease models may require protocol optimization.
- Model primarily reflects acute demyelination; chronic or remyelination studies may need additional validation.
